Grand Pharmaceutical Group Stock Value
Grand Pharmaceutical Group Company Info
EPS Growth 5Y
-7,61%
Market Cap
HK$24,02 B
Long-Term Debt
HK$1,84 B
Quarterly earnings
05/19/2026 (E)
Dividend
HK$0,17
Dividend Yield
2,46%
Founded
1995
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
HK$11,88
73.18%
Last Update: 04/11/2026
Analysts: 4
Highest Price Target HK$12,00
Average Price Target HK$11,88
Lowest Price Target HK$11,70
In the last five quarters, Grand Pharmaceutical Group’s Price Target has risen from HK$4,17 to HK$7,60 - a 82,25% increase. One analysts predict that Grand Pharmaceutical Group’s share price will increase in the coming year, reaching HK$11,88. This would represent an increase of 73,18%.
Top growth stocks in the health care sector (5Y.)
What does Grand Pharmaceutical Group do?
Grand Pharmaceutical Group Limited (Grand Pharmaceutical) engages primarily in the manufacture and sale of pharmaceutical preparations, medical devices, biotechnology products, health products, and specialized pharmaceutical raw materials.
Business Segments
The company operates within a singular reportable segment, which encompasses the manufacture and sales of various pharmaceutical goods and services. This broad business segment includes pharmaceutical preparations, medical devices, and biot...
Grand Pharmaceutical Group Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical Products:** approx. 60%
**Medical Devices:** approx. 25%
**Biotechnology and Research:** approx. 15%
**TOP 3 Markets:**
1. **China:** approx. 55%
2. **USA:** approx. 20%
3. **Europe:** approx. 15%
Grand Pharmaceutical Group Limited generates the majority of its revenu...
At which locations are the company’s products manufactured?
**Production Sites:** China, Hong Kong
Grand Pharmaceutical Group Limited produces the majority of its products in China, where it has several production facilities. This strategic placement enables the company to benefit from the cost-effective production opportunities in the region.
Additionally...
What strategy does Grand Pharmaceutical Group pursue for future growth?
**Revenue Growth:** Estimated 10-12% annually (2025 forecast)
**R&D Investments:** Increased by 20% (2024)
Grand Pharmaceutical Group Limited is pursuing a growth strategy that heavily focuses on research and development (R&D). The company increased its R&D investments by 20% in 202...
Which raw materials are imported and from which countries?
**Main raw materials:** Pharmaceutical active ingredients, chemicals
**Countries of origin:** China, India, USA
Grand Pharmaceutical Group Limited mainly imports pharmaceutical active ingredients and chemicals needed for the production of its products. These raw materials mainly come from China an...
How strong is the company’s competitive advantage?
**Market Share:** Estimated at 5-7% in the Asian pharmaceutical market (2025)
**Research & Development (R&D) Expenses:** 12% of revenue (2024)
**Patent Portfolio:** Over 200 active patents (2025)
Grand Pharmaceutical Group Limited has a moderate competitive advantage in the Asian pharmace...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 42% (2025, estimated)
**Insider Buys/Sells:** No significant transactions in the last 12 months (2025, estimated)
The institutional investor share in Grand Pharmaceutical Group Limited is estimated to be around 42%. This indicates a strong interest from institution...
What percentage market share does Grand Pharmaceutical Group have?
**Market share of Grand Pharmaceutical Group Limited:** Estimated 3-5% (2025)
**Main competitors and their market shares:**
1. **Sinopharm Group Co. Ltd.:** 15%
2. **Shanghai Pharmaceuticals Holding Co. Ltd.:** 12%
3. **China Resources Pharmaceutical Group Ltd.:** 10%
4. **CSPC Pharmaceutical Group...
Is Grand Pharmaceutical Group stock currently a good investment?
**Revenue Growth:** 8.5% (2024)
**Profit Growth:** 10.2% (2024)
**R&D Expenses:** 12% of revenue (2024)
Grand Pharmaceutical Group Limited recorded solid revenue growth of 8.5% in 2024, accompanied by a profit growth of 10.2%. This indicates effective cost control and successful implement...
Does Grand Pharmaceutical Group pay a dividend – and how reliable is the payout?
**Dividend yield:** 3.5% (2025, estimated)
**Dividend history:** Consistent payout over the last 5 years
Grand Pharmaceutical Group Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2025 is around 3.5%, which...
